诺思格股权纠纷案再起波澜 68岁药物专家不服二审判决申请再审已立案

Core Viewpoint - The ongoing legal dispute between NuoSiGe and its actual controller Wu Jie, along with expert Zhong DaFang, has attracted significant public attention, particularly due to the involvement of Zhong, a well-known figure in drug research and development [2][6]. Group 1: Legal Dispute Overview - NuoSiGe received a notice from the Supreme People's Court regarding a civil case for retrial initiated by Zhong DaFang, who is dissatisfied with the second-instance ruling by the Beijing High People's Court [2][5]. - The dispute originated from a compensation claim of 180 million yuan, which began before the company's IPO in August 2022 [2][3]. - Zhong DaFang had previously raised concerns about significant omissions in NuoSiGe's prospectus, leading to investigations by the underwriting agency and the Shenzhen Stock Exchange [3]. Group 2: Financial Performance and Business Impact - NuoSiGe's revenue is heavily reliant on the domestic market, with nearly 90% of its income sourced from within China, linking its performance directly to the development of the domestic innovative drug industry [6]. - In 2024, the company's revenue from clinical trial operation services, its largest business segment, declined by nearly 10% year-on-year [6]. - Despite the overall revenue decline, the income from biological sample testing services, which is linked to Suzhou Haike, a company founded by Zhong DaFang, saw a significant year-on-year increase of approximately 74% [6][7]. Group 3: Future Outlook - NuoSiGe's stock price has shown limited volatility, with a year-to-date decline of 3.20%, despite a broader market rally in the innovative drug sector [6]. - The company reported a revenue of 173 million yuan in the first quarter of this year, a decrease of 2.53% year-on-year, while net profit attributable to shareholders increased by 13.12% [7]. - Analysts predict that the domestic clinical CRO industry may recover due to new policies, potentially providing NuoSiGe with opportunities for rapid growth [7][8].